Medical
 A research published in 2003 by the medical journal "Pediatrics", which analysed the audio transcripts of 13 visits of Spanish-speaking patients to an American paediatrics clinic, found out that official interpreters made 231 errors, 53 percent of them were judged to have the potential to cause health problems. Amongst the errors were a parent being told to put steroid cream on a child's entire body instead of just the face, another one being asked to administrate an oral antibiotic in the infant's ears instead of the mouth, and an interpreter telling a mother not to answer questions about sexually transmitted diseases or drug use.
At Today Translations, we put extra diligence when dealing with healthcare translation or interpreting. Because we believe that ultimately a good service can be the difference between life and death, we work with chartered healthcare professionals with several years' experience in the sector.
Our Services
We translate a huge variety of documents, including medication literature, patents and any type of public-oriented information (e.g. Parkinson syndrome, Sexually Transmitted Diseases).
CLICK HERE TO GET A QUOTE
We provide virtually all varieties of interpreting within the course of clinical services or healthcare conferences (including for large groups, small groups or remote interpreting). All our interpreters have several years' sector experience and hold higher education degrees in medical or health-related studies.
CLICK HERE TO GET A QUOTE
MAJOR CARDS ACCEPTED
Healthcare Industry: The Pressure to Deliver Cost-Effective Solutions
NATURE OF THE INDUSTRY
According to Euromonitor, the 2004 OTC (Over-the-Counter) healthcare market is led by Pfizer (United States), followed by Johnson & Johnson (United States), GlaxoSmithKline (United Kingdom), Wyeth (United States), Taisho Pharmaceutical (Japan), Novartis (Switzerland), Boehringer Sohn (Germany), Bayer (Germany), Roche (Switzerland) and Otsuka Pharmaceutical (Japan).
Worldwide, the healthcare sector is one of the fastest expanding industries. The US accounts for 43% of the world healthcare expenditure (16% of the GDP) compared to 11% of Japan, 8% of Germany and 3% of the UK. The growth in demand is driven by peoples' rising expectations and the fast-developing science base. There's a wide range of products, which are diversified and fragmented.
REGULATION & POLICY
Legislation is becoming more onerous, including environmental aspects, European directives and complexity arising from global regulatory harmonisation. There are, nevertheless, opportunities for new products that meet regulatory drivers.
ECONOMICS
The sector has a very high multiplier effect in economic terms. The political vow to contain funding and increase control is leading to purchases based on cost-efficiency and measured / improved results within tight budgets. This creates a high impact on suppliers, increasing pressure on prices and narrowing margins. Higher concentration on major sectors is getting inevitable.
PROCUREMENT
The supply chain has been faced with changes in buying patterns and the need for greater management of purchasing and supply. Currently in the UK, where the ultimate user (patient) is not the buyer, marketing is targeted to those with the budget rather than the users.
Moreover, the traditional value-for-money models used in procurement of commodities are not appropriate for medical devices and systems. There is a need to be able to carry out cost-benefit analyses more effectively, since often the costs of new technology will fall on one 'silo' while the benefits will be felt in another.
DEMOGRAPHICS
Developed countries are experiencing ageing populations and an increased focus on chronic disease management. On the flipside, there are large numbers of poor people without access to healthcare in developing nations.
HEALTHCARE DELIVERY
Services are being rolled back from acute hospitals to primary care for practical and cost reasons. Currently 80% of the UK industry's sales are to hospitals. The development of private healthcare facilities and services predominates in developed countries, giving US companies a competitive advantage over their UK counterparts. A newly emerging sub-sector of private firms is providing healthcare support at home.
(BIO)TECHNOLOGY
Healthcare technologies constitute some of the highest value commercial outcomes from national public and private sector research / development. Growth in the area is driven by rising expectation and demand from people seeking prolonged quality of life and cures for all ills, but also by a rapidly developing science base, which is enabling new diagnostics and treatments to be developed.
Biotechnology has an extraordinary range of applications ranging from healthcare, agriculture and food to industrial and fine chemicals. The biotech field of the healthcare sector is characterised by businesses whose products or services depend to a significant extent on the application of technology related to the manipulation and use of living bodies.
|
